Chronic kidney disease (CKD) is a major health problem that has devastating metabolic consequences. Osteoporosis is one of the pivotal metabolic disorders that occurs in CKD patients. Osteoporosis in CKD patients is complex and there is no consensus regarding its management. Most nephrologists are very familiar with management of Mineral and Bone Disorders (MBD) in CKD patients however there is a big gap in diagnosis and treatment of osteoporosis in this patient population. Anti-restorative therapies are traditionally used to treat osteoporosis, but when it comes to CKD patients there are barriers in using these medications. Bone loss in CKD patients could be related not only to increased bone resorption, but also to decreased bone formation as well. Specifically, in osteoporosis management in CKD patients we need to understand the underlying mechanism behind bone loss.
The field of precision medicine has grown enormously in the last few decades. However, the application of this concept has been vividly evolved by the new developments in various sciences such as genomics, proteomics, metabolomics, use of biomarkers, and wide utilization of large data sets. In this Research Topic, we are focusing on how to treat osteoporosis in CKD patients precisely. Using a precision medicine approach in osteoporosis management in CKD patients would not only improve the efficacy but also reduce the adverse events of various pharmacological and non-pharmacological interventions. The ultimate goal of this work is trying to fill the gap in osteoporosis management in CKD patients.
The goal of this Research Topic is to highlight the importance of identifying the exact pathology behind bone loss that will help to precisely manage osteoporosis. Using this approach would help to prevent fractures and improve patients' quality of life. Accordingly, we encourage authors to address the following themes:
• Diagnosis of osteoporosis
• CKD-MBD.
• Available anti-osteoporotic agents
• Future directions in using precision medicine in osteoporosis management in CKD patients
Chronic kidney disease (CKD) is a major health problem that has devastating metabolic consequences. Osteoporosis is one of the pivotal metabolic disorders that occurs in CKD patients. Osteoporosis in CKD patients is complex and there is no consensus regarding its management. Most nephrologists are very familiar with management of Mineral and Bone Disorders (MBD) in CKD patients however there is a big gap in diagnosis and treatment of osteoporosis in this patient population. Anti-restorative therapies are traditionally used to treat osteoporosis, but when it comes to CKD patients there are barriers in using these medications. Bone loss in CKD patients could be related not only to increased bone resorption, but also to decreased bone formation as well. Specifically, in osteoporosis management in CKD patients we need to understand the underlying mechanism behind bone loss.
The field of precision medicine has grown enormously in the last few decades. However, the application of this concept has been vividly evolved by the new developments in various sciences such as genomics, proteomics, metabolomics, use of biomarkers, and wide utilization of large data sets. In this Research Topic, we are focusing on how to treat osteoporosis in CKD patients precisely. Using a precision medicine approach in osteoporosis management in CKD patients would not only improve the efficacy but also reduce the adverse events of various pharmacological and non-pharmacological interventions. The ultimate goal of this work is trying to fill the gap in osteoporosis management in CKD patients.
The goal of this Research Topic is to highlight the importance of identifying the exact pathology behind bone loss that will help to precisely manage osteoporosis. Using this approach would help to prevent fractures and improve patients' quality of life. Accordingly, we encourage authors to address the following themes:
• Diagnosis of osteoporosis
• CKD-MBD.
• Available anti-osteoporotic agents
• Future directions in using precision medicine in osteoporosis management in CKD patients
